Ownership Summary
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) appears in 11 institutional 13F filings for the quarter ending March 2026.
- Collectively, these holders controlled 3077.8% of Creative Medical Technology Holdings's outstanding shares in March 2026, down from 4098.7% in December 2025.
- Their total shares held in CELZ increased 213.89% from the prior quarter, while the number of investors in Creative Medical Technology Holdings decreased 8.33% year over year.
- During the quarter, 8 of these 11 funds increased positions in CELZ, 2 reduced exposure, and 1 held steady.
- In total, institutional investors held 96.76K shares in Creative Medical Technology Holdings as of March 2026, up by 65.94K shares quarter on quarter, and down 104.82K shares year over year.
- As of March 31, 2026, GEODE CAPITAL MANAGEMENT, LLC held the largest stake in Creative Medical Technology Holdings with 38.29K shares, accounting for 1217.88% of total shares outstanding.
- Leading buyers of Creative Medical Technology Holdings shares for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (20.35K), XTX Topco Ltd (14.26K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (10.47K), GEODE CAPITAL MANAGEMENT, LLC (9.82K), VANGUARD FIDUCIARY TRUST CO (5.52K).
- The largest sales of CELZ for the quarter ending March 2026 came from Tower Research Capital LLC (TRC) (223), UBS Group AG (10).
- Per Business Quant data, the top 10 holders of Creative Medical Technology Holdings for the quarter ending March 2026 are GEODE CAPITAL MANAGEMENT, LLC (38.29K), VANGUARD CAPITAL MANAGEMENT LLC (20.35K), XTX Topco Ltd (14.26K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (10.47K), VANGUARD FIDUCIARY TRUST CO (5.52K), Wells Fargo & Company/Mn (5.0K), Tower Research Capital LLC (TRC) (2.09K), Morgan Stanley (534), FMR LLC (250), SBI Securities Co., Ltd. (1).